Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT ID: NCT00005025
Last Updated: 2013-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
INTERVENTIONAL
2000-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the efficacy and safety of in vivo gene therapy with herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) followed by ganciclovir in women with refractory or relapsed ovarian epithelial adenocarcinoma, fallopian tube cancer, or peritoneal cancer.
* Determine any development of systemic immunity to this regimen or tumor in these patients.
* Determine the toxic effects of intraperitoneal HSVtk VPC in these patients.
OUTLINE: All patients receive an intraperitoneal catheter prior to infusion.
Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over 15-60 minutes on day 0, followed by ganciclovir IV 2 times daily on days 28-41. Treatment repeats for up to 3 courses in patients with stable or responsive disease.
Patients are followed every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 14-20 patients will be accrued for this study within 18-24 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
herpes simplex thymidine kinase
ganciclovir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma, fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy exists
* Must have tissue available from tumor biopsy to grow tumor cells ex vivo
* Must have failed standard therapy with both a platinum agent (cisplatin or carboplatin) and paclitaxel
* Site of disease must be less than 5 cm in greatest diameter
* Evaluable disease by CT scan, physical exam, or laparoscopy
* No significant peritoneal fibrosis either from disease or prior surgery
* Surgical lysis of adhesions allowed
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC greater than 2,000/mm3
* Absolute neutrophil count at least 1,000/mm3
* Platelet count at least 50,000/mm3
* Hemoglobin at least 8.5 g/dL (without transfusion)
Hepatic:
* Bilirubin no greater than 2.0 mg/dL
* SGOT or SGPT no greater than 4 times upper limit of normal (ULN)
* Alkaline phosphatase no greater than 4 times ULN
* Hepatitis B surface antigen test required prior to study if transaminases greater than 2.0 times ULN
* No hepatitis B surface antigen
* Amylase normal
* PT and PTT normal
Renal:
* Creatinine no greater than 2.0 mg/dL OR
* Creatinine clearance at least 50 mL/min
Cardiovascular:
* No cardiac dysfunction by history and exam
* No ischemic heart disease that may be considered anesthetic or operative risk
Pulmonary:
* No lung disease that may be considered anesthetic or operative risk
Other:
* HIV negative
* Not pregnant or nursing
* No acute viral, bacterial, or fungal infection requiring medication within 14 days prior to study
* No patient with greater than 2 L of ascites at the time of intraperitoneal infusion
* No underlying condition that would preclude compliance
* No allergies to study reagent
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
* No concurrent chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
Other:
* No concurrent high dose vitamin regimens
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
John Stoddard Cancer Center at Iowa Methodist Medical Center
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Joseph Link, MD
Role: STUDY_CHAIR
John Stoddard Cancer Center at Iowa Methodist Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Human Gene Therapy Research Institute
Des Moines, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGTRI-0105
Identifier Type: -
Identifier Source: secondary_id
NCI-V00-1584
Identifier Type: -
Identifier Source: secondary_id
CDR0000067546
Identifier Type: -
Identifier Source: org_study_id